Chingkai Kung
Chingkai Kung is a PhD candidate at National Yang Ming Chiao Tung University. His research applies artificial intelligence to in vitro studies, with a focus on fluorescence imaging, multi-omics analysis, and in silico prediction. He specializes in combining complementary information from imaging and omics measurements to support experimental interpretation, guide in vitro decision-making, and enable cross-modal prediction. His work aims to make in vitro data more interpretable and decision-ready. He currently works as an AI R&D Engineer in Bioinformatics at Anivance AI.
About Anivance AI
Founded in 2024, Anivance AI is building the human validation infrastructure for AI-driven drug development. Its platform transforms human-relevant biology into reproducible, decision-grade evidence through standardized and scalable workflows. The company works with pharmaceutical companies, medical centers, and regulatory institutions worldwide to bridge computational prediction with human-relevant biological validation. In 2026, Anivance AI was selected as one of four global technology providers for the FNIH NAMs Pilot Program in the United States.
